Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 1.00 |
| ▸ | CNR1 | P21554 | 12/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31545961 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| Dexanabinol SCHEMBL1517462 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| SCHEMBL17414497 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| Dexanabinol SCHEMBL3746646 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| Dexanabinol SCHEMBL1649687 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| Dexanabinol SCHEMBL1517460 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| Dexanabinol SCHEMBL5464644 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| Dexanabinol SCHEMBL5449597 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| SCHEMBL17414495 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| Dexanabinol SCHEMBL31545009 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495029-B2 | Prodrugs of (2R)-2-propyloctanoic acid for the treatment of stroke | MERCK & CO., INC (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080132488-A1 | Prodrugs of (2R)-2-Propyloctanoic Acid For the Treatment of Stroke | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20070213369-A1 | NOVEL NON-PSYCHOTROPIC CANNABINOIDS | PHARMOS CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
| US-7235584-B2 | Non-psychotropic cannabinoids | PHARMOS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| EP-0765160-B1 | DEXANABINOL DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS | UNIV RAMOT (IL) | 2003-04-16 | — | — | EP | disclosed |
| US-6096740-A | BLOCK N-METHYL-ASPARTATE | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 2000-08-01 | — | — | US | disclosed |
| EP-0765160-A4 | — | — | 1997-04-09 | — | — | EP | disclosed |
| EP-0765160-A1 | DEXANABINOL DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS | RAMOT UNIVERSITY, AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. (IL) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995020958-A1 | DEXANABINOL DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 1995-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132488-A1 | Prodrugs of (2R)-2-Propyloctanoic Acid For the Treatment of Stroke | APEH, HCAR2, PTGDR | CNR2 255/4885CNR1 656/4885GLRA1 987/4885 |
| US-20070213369-A1 | NOVEL NON-PSYCHOTROPIC CANNABINOIDS | CNR1, CNR2, CHRNA6 | CNR2 2/4885CNR1 1/4885GLRA1 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.